BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 17470364)

  • 1. Promoter methylation, mutation, and genomic deletion are involved in the decreased NDRG2 expression levels in several cancer cell lines.
    Liu N; Wang L; Liu X; Yang Q; Zhang J; Zhang W; Wu Y; Shen L; Zhang Y; Yang A; Han H; Zhang J; Yao L
    Biochem Biophys Res Commun; 2007 Jun; 358(1):164-9. PubMed ID: 17470364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-regulation of NDRG2 gene expression in human colorectal cancer involves promoter methylation and microRNA-650.
    Feng L; Xie Y; Zhang H; Wu Y
    Biochem Biophys Res Commun; 2011 Mar; 406(4):534-8. PubMed ID: 21352815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NDRG2 is a candidate tumor-suppressor for oral squamous-cell carcinoma.
    Furuta H; Kondo Y; Nakahata S; Hamasaki M; Sakoda S; Morishita K
    Biochem Biophys Res Commun; 2010 Jan; 391(4):1785-91. PubMed ID: 20045673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced expression of N-Myc downstream-regulated gene 2 in human thyroid cancer.
    Zhao H; Zhang J; Lu J; He X; Chen C; Li X; Gong L; Bao G; Fu Q; Chen S; Lin W; Shi H; Ma J; Liu X; Ma Q; Yao L
    BMC Cancer; 2008 Oct; 8():303. PubMed ID: 18940011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression of candidate tumor suppressor gene N-Myc downstream-regulated gene 2 in colon cancer].
    Chu DK; Zhang J; Shi H; Dong GL; Liu XP; Wang WZ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Jul; 11(4):354-7. PubMed ID: 18636358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KLF5 is frequently deleted and down-regulated but rarely mutated in prostate cancer.
    Chen C; Bhalala HV; Vessella RL; Dong JT
    Prostate; 2003 May; 55(2):81-8. PubMed ID: 12661032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional and clinical evidence for NDRG2 as a candidate suppressor of liver cancer metastasis.
    Lee DC; Kang YK; Kim WH; Jang YJ; Kim DJ; Park IY; Sohn BH; Sohn HA; Lee HG; Lim JS; Kim JW; Song EY; Kim DM; Lee MN; Oh GT; Kim SJ; Park KC; Yoo HS; Choi JY; Yeom YI
    Cancer Res; 2008 Jun; 68(11):4210-20. PubMed ID: 18519680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of MTUS1 in human colon tumors.
    Zuern C; Heimrich J; Kaufmann R; Richter KK; Settmacher U; Wanner C; Galle J; Seibold S
    Oncol Rep; 2010 Jan; 23(1):183-9. PubMed ID: 19956880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.
    Jiang Y; Tong D; Lou G; Zhang Y; Geng J
    Pathobiology; 2008; 75(4):244-51. PubMed ID: 18580070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression and significance of new candidate tumor suppressor gene N-Myc downstream-regulated gene 2 in colorectal cancer].
    Shi H; Wang WZ; Yao LB; Zhang J; Yin Q; Xu CS; Chu DK; Dong GL; Zhang HW; Li JP
    Zhonghua Wei Chang Wai Ke Za Zhi; 2009 May; 12(3):281-4. PubMed ID: 19434539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A quantitative analysis of N-myc downstream regulated gene 2 (NDRG 2) in human tissues and cell lysates by reverse-phase protein microarray.
    Park MY; Choi SC; Lee HS; Kim D; Baek KE; Kim JT; Lim JS; Yeom YI; Chung JW; Kim JW; Myung PK; Lee HG; Kim JW; Song EY
    Clin Chim Acta; 2008 Jan; 387(1-2):84-9. PubMed ID: 17936257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma.
    Lusis EA; Watson MA; Chicoine MR; Lyman M; Roerig P; Reifenberger G; Gutmann DH; Perry A
    Cancer Res; 2005 Aug; 65(16):7121-6. PubMed ID: 16103061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer.
    Melotte V; Lentjes MH; van den Bosch SM; Hellebrekers DM; de Hoon JP; Wouters KA; Daenen KL; Partouns-Hendriks IE; Stessels F; Louwagie J; Smits KM; Weijenberg MP; Sanduleanu S; Khalid-de Bakker CA; Oort FA; Meijer GA; Jonkers DM; Herman JG; de Bruïne AP; van Engeland M
    J Natl Cancer Inst; 2009 Jul; 101(13):916-27. PubMed ID: 19535783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
    Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
    Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppressed expression of NDRG2 correlates with poor prognosis in pancreatic cancer.
    Yamamura A; Miura K; Karasawa H; Morishita K; Abe K; Mizuguchi Y; Saiki Y; Fukushige S; Kaneko N; Sase T; Nagase H; Sunamura M; Motoi F; Egawa S; Shibata C; Unno M; Sasaki I; Horii A
    Biochem Biophys Res Commun; 2013 Nov; 441(1):102-7. PubMed ID: 24134849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and promoter methylation of the RASSF1A gene in sporadic breast cancers in Chinese women.
    Li Y; Wei Q; Cao F; Cao X
    Oncol Rep; 2008 May; 19(5):1149-53. PubMed ID: 18425370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor suppressor candidate gene, NDRG2 is frequently inactivated in human glioblastoma multiforme.
    Zhou B; Tang Z; Deng Y; Hou S; Liu N; Lin W; Liu X; Yao L
    Mol Med Rep; 2014 Aug; 10(2):891-6. PubMed ID: 24840052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of human NDRG2 by myeloid dendritic cells inhibits down-regulation of activated leukocyte cell adhesion molecule (ALCAM) and contributes to maintenance of T cell stimulatory activity.
    Choi SC; Kim KD; Kim JT; Kim JW; Lee HG; Kim JM; Jang YS; Yoon DY; Kim KI; Yang Y; Cho DH; Lim JS
    J Leukoc Biol; 2008 Jan; 83(1):89-98. PubMed ID: 17911180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
    Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
    Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.
    Wang R; Wang X; Li B; Lin F; Dong K; Gao P; Zhang HZ
    Breast Cancer Res Treat; 2009 Sep; 117(1):45-54. PubMed ID: 18791823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.